Literature DB >> 3924626

The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors.

E von Angerer, J Prekajac, M Berger.   

Abstract

The antineoplastic activity of the antiestrogen 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) was determined in several estrogen-dependent mammary tumor models. The growth of the DMBA-induced rat mammary carcinoma was inhibited by doses ranging from 1 to 12 mg/kg. The maximum decrease of tumor area was 67% (control + 635%). D 16726 was also active against MNU-induced rat mammary tumors and transplanted MXT tumors of the mouse. The growth of estrogen receptor-positive MCF-7 breast cancer cells was inhibited by the hydroxy derivative D 15414 (10(-8)-10(-5) M). Because of the high binding affinity of D 15414 for the estrogen receptor (RBA 6.7-10.0) and the lack of activity against hormone-independent MDA-MB 231 breast cancer cells, a specific mode of action involving the estrogen receptor is likely.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924626     DOI: 10.1016/0277-5379(85)90048-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  5 in total

1.  Evaluation of the antitumour activity of coumarin in prostate cancer models.

Authors:  A Maucher; M Kager; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Studies on the mammary tumor-inhibiting effects of diethylstilbestrol and its mono- and diphosphate.

Authors:  M R Schneider; E von Angerer; J Prekajac; W P Brade
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Effect of zindoxifene on experimental prostatic tumours of the rat.

Authors:  M R Schneider; C D Schiller; A Humm; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  The inhibitory effect of 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-6-hydroxyindole (D 15413) on estrogen-dependent mammary tumors.

Authors:  E von Angerer; J Prekajac; M R Schneider; M R Berger
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.

Authors:  R C Stein; M Dowsett; D C Cunningham; J Davenport; H T Ford; J C Gazet; E von Angerer; R C Coombes
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.